What is the market's earnings forecast for Ultragenyx next quarter?

What guidance did Ultragenyx's management provide for the next earnings period?

Did Ultragenyx beat or miss consensus estimates last quarter?

What were the key takeaways from Ultragenyx's earnings call?

What is Ultragenyx's gross profit margin?

What is the revenue and EPS growth rate for Ultragenyx year over year?

What is Ultragenyx's latest dividend and current dividend yield?

What does Ultragenyx do and what are its main business segments?

- **Strategic Restructuring**: 10% workforce reduction to achieve 2027 profitability, focusing on 3 new launches (UX111, DTX401, GTX-102).
- **Revenue Growth**: 2025 revenue up 20% to $673M; 2026 guidance $730M-$760M (+8%-13%).
- **Pipeline Momentum**: DTX401 PDUFA Q3 2026, UX111 resubmission underway, GTX-102 Phase III data H2 2026.
- **PRV Potential**: 2 vouchers could add $100M+ to cash position, supporting 2027 profitability.
- **Commercial Strength**: Crysvita, Dojolvi, Evkeeza growing across 35+ countries, Japan launches in 2026.

**【CEO Summary Section】**
- Announced strategic restructuring plan to reduce operating expenses by 10% (130 FTEs), aligning resources with high-impact opportunities.
- Resubmitted UX111 BLA for MPS IIIA, receiving incomplete response letter requiring additional CMC documentation.
- 2025 revenue grew 20% YoY to $673M, driven by Crysvita (20% growth), Dojolvi (9%), and Evkeeza (84%).
- Targeting profitability in 2027 through cost reductions and 3 new product launches (UX111, DTX401, GTX-102).

**【CFO Financial Commentary】**
- 2025 GAAP net loss: $575M; Non-GAAP EPS: $1.08 (exceeds expectations).
- 2026 revenue guidance: $730M-$760M (+8%-13%), with Crysvita at $500M-$520M.
- R&D/S&M expenses expected flat to down low single digits in 2026, 15%+ decline in 2027.
- Cash balance: $38M as of Dec 31, 2025.

**【Chief Commercial Officer Summary】**
- Crysvita: 2025 revenue $481M (+17%), Brazil/Latin America key growth drivers.
- Dojolvi: $96M (+9%), Japan launch Q2 2026.
- Evkeeza: $59M (+84%), 350+ patients across 20 countries.
- GTX-102: Phase III data expected H2 2026, high patient retention (>90%).

**【CMO Clinical Updates】**
- DTX401 (GSD Ia): BLA submission complete, PDUFA date Q3 2026.
- UX111 (MPS IIIA): Long-term data shows sustained clinical benefit, resubmission underway.
- UX701 (Wilson disease): Cohort 4 enrollment complete, data expected 2026.
- GTX-102 (Angelman): Phase III Aspire study on track for H2 2026 readout.

**【Q&A Highlights】**
- Angelman study: Bayley-4 cognition as primary endpoint, 90%+ patient retention in extension.
- PRV monetization: Potential $100M+ impact, 2 vouchers expected from UX111/DTX401 approvals.
- Regulatory challenges: FDA requiring additional CMC documentation for UX111, but confident in program strength.
- Launch trajectory: GSD Ia expected steady demand, MPS IIIA urgent need driving rapid uptake.

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

- **$400M Royalty Financing**: Strengthens balance sheet for 2026 launches, with payments deferred until 2028.
- **Clinical Catalysts**: UX143 Phase III data in Q4 2025/Q1 2026; GTX-102 Phase III readout in H2 2026.
- **Revenue Growth**: 2025 guidance of $640-670 million (14%-20% YoY), driven by Crysvita ($460-480M) and pipeline expansion.
- **Profitability Path**: 2027 GAAP profitability with disciplined spending and royalty proceeds.

**【CEO Summary Section】**
- **Strategic Financial Move**: Secured $400 million through Crysvita royalty sale with OMERS, deferred payments until 2028, enhancing liquidity for upcoming launches.
- **Clinical Momentum**: GTX-102 (Angelman syndrome) Phase III Aspire study nearing data readout in H2 2026; UX143 (osteogenesis imperfecta) Phase III data expected in December/January 2026.
- **Revenue Growth**: 2025 total revenue guidance of $640-670 million (14%-20% YoY growth), driven by Crysvita ($460-480 million) and expanding product portfolio.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $160 million (+15% YoY), operating expenses $331 million (R&D $216 million, SG&A $87 million). Net loss $180 million, cash balance $447 million post-funding.
- **Financial Discipline**: Path to 2027 GAAP profitability with disciplined spending and $400 million royalty proceeds supporting pipeline execution.

**【Q&A Highlights】**
- **OI Data Timing**: UX143 Phase III data expected in December/January 2026; both Orbit and Cosmic studies powered for success, with potential for approval even if one misses.
- **Setrusumab Commercial Strategy**: Anticipated as chronic treatment, targeting broader OI population (50%-100% larger than XLH) with Crysvita-like pricing.
- **Competitive Angelman Landscape**: GTX-102 ASO potency and patient support programs key differentiators; Aurora study to expand genotype coverage.


Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

- **Clinical Momentum**: 5 Phase III programs advancing; GTX-102 Phase III enrollment 129/129 ahead of plan. UX143 OI trials on track for end-2025 readout. 
- **Revenue Growth**: 20% YTD to $306M; 2025 guided to $640-670M. Crysvita, Dojolvi, Evkeeza driving global expansion. 
- **Financial Discipline**: $539M cash; 2027 GAAP profitability path via expense control and PRV receipts. 
- **FDA Engagement**: Productive UX111 CRL discussions; Breakthrough Therapy GTX-102 highlights neurology innovation. 
- **Risk Management**: Delays in UX111/DTX401 resolved via expense deferrals; AAV safety maintained with low-dose strategy.

**【CEO Summary Section】**
- Celebrated 15-year milestone with 4 approved programs and 5 Phase III clinical trials. 
- UX143 (setrusumab) for OI: Phase III trials (Orbit/Cosmic) on track for end-2025 readout; interim DMC review recommended continuation. GTX-102 (ASO for Angelman syndrome) received FDA Breakthrough Therapy Designation; Phase III Aspire study enrolled 129 patients ahead of plan. 
- Commercial revenue grew 20% YTD to $306M, guided to $640-670M for 2025. Crysvita, Dojolvi, Evkeeza, and Mepsevii driving growth across geographies. 
- Emphasized disciplined expense management to achieve GAAP profitability in 2027.

**【CFO Financial Commentary】**
- Q2 2025 total revenue: $166M (+13% QoQ, +20% YoY). Crysvita ($120M), Dojolvi ($23M), Evkeeza ($15M), Mepsevii ($8M) all growing. 
- Operating expenses: $274M (R&D: $165M, SG&A: $87M). Net loss: $115M ($1.17/share). 
- Cash position: $539M (includes $80M ATM proceeds). 2025 net cash use expected to modestly increase due to UX111/DTX401 delays. 
- 2025 guidance: $640-670M total revenue (Crysvita: $460-480M, Dojolvi: $90-100M). 

**【CMO Clinical Updates】**
- UX111 (MPS IIIA): Received CRL with request for updated clinical/biomarker data; Type A meeting planned. DTX401 (GSDIa): BLA submission on track for Q4 2025. UX701 (Wilson disease): Cohort 4 enrollment underway with immunomodulation. 
- GTX-102: Aspire study enrollment completed; Aurora study to begin H2 2025 for expanded patient populations. 

**【Q&A Highlights】**
- **FDA Interactions**: CEO confident in productive FDA engagement; UX111 CRL resolution expected via Type A meeting. 
- **OI Trial Design**: Orbit/Cosmic powered for 50% fracture reduction; MDRI endpoint allocated 10% alpha. 
- **Cash Management**: Delayed expenses to bridge PRV receipts; 3 PRVs (UX111, DTX401, UX143) expected to fund 2027 GAAP path. 
- **AAV Safety**: Low-dose AAV platform maintained strong safety profile; Cohort 4 UX111 testing enhanced immunosuppression.

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

- **Revenue Growth Surpasses Expectations**: Q1 2025 revenue up 28% YoY, with Crysvita leading Latin America growth (52% YoY). 2025 guidance of $640M-$670M reflects strong pipeline execution.
- **Pipeline Breakthroughs**: UX143 Phase 3 interim analysis mid-2025 with 67% fracture reduction in Phase 2; DTX401 BLA submission on track for mid-2025 with 60% cornstarch reduction.
- **Financial Health**: $563M cash position and improving operational efficiency; targeting GAAP profitability by 2027.
- **Regulatory Confidence**: UX111 BLA review progressing on track for August 2025 PDUFA date; manufacturing inspections and regulatory interactions proceeding as planned.
- **Competitive Edge**: Angelman ASO space poised for multiple therapies; GTX-102's long-term efficacy and patient experience seen as key differentiators.


**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue of $139M, up 28% YoY, driven by Crysvita's 52% growth in Latin America and Turkey. Total 2025 guidance remains $640M-$670M, reflecting strong demand across products.
- **Pipeline Momentum**: Multiple late-stage programs advancing, including UX143 (OI) Phase 3 interim analysis expected mid-2025, GTX-102 (Angelman) on track for 2026 data, and DTX401 (GSD1a) BLA submission mid-2025.
- **Regulatory Confidence**: UX111 (Sanfilippo) BLA review progressing on track for August 2025 PDUFA date; manufacturing inspections and regulatory interactions proceeding as planned.

**【CFO Financial Commentary】**
- **Q1 Financials**: GAAP net loss of $151M (-$1.57/share) due to $45M milestone payments. Non-GAAP metrics highlight strong cash position ($563M) and operating efficiency improvements.
- **Revenue Breakdown**: Crysvita ($103M, 25% YoY), Dojolvi ($17M, steady growth), Evkeeza ($11M, expanding outside U.S.), Mepsevii ($8M). 2025 Crysvita guidance: $460M-$480M (12%-17% YoY growth).
- **Cash Flow Management**: Q1 net cash used in operations $166M, expected to decline in 2025H2; targeting GAAP profitability by 2027.

**【CMO Clinical Updates】**
- **UX143 (OI)**: Phase 3 ORBIT study nearing 12-month enrollment; interim analysis mid-2025. Phase 2 data shows 67% fracture reduction (p=0.0014 at 14 months), supporting potential IA2 success.
- **DTX401 (GSD1a)**: BLA submission mid-2025 with 60% cornstarch reduction in DTX401 group, 64% in placebo crossover. Manufacturing readiness confirmed.
- **GTX-102 (Angelman)**: On track for 2026 data; 120-patient pivotal study enrolling globally with enhanced immunomodulation regimen.

**【Q&A Key Takeaways】**
- **OX143 Interim Analysis**: High confidence in IA2 success (p<0.01 threshold) due to Phase 2 data trends; COSMIC study unblinding contingent on ORBIT results.
- **Competitive Landscape**: Angelman ASO space expected to support multiple therapies; GTX-102's long-term efficacy and patient experience seen as differentiators.
- **Regulatory Environment**: CBER leadership changes viewed as industry-wide concern, but UX111 BLA strength (clinical + CMC data) mitigates risk.
- **Commercial Execution**: Crysvita adult uptake in Latin America and U.S. driving growth; Evkeeza poised for meaningful contribution post-reimbursement wins.


Ultragenyx Pharmaceutical (RARE)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 revenue of $560 million (+29%) driven by Crysvita ($410M) and Latin America expansion. 2025 guidance: $640-$670 million.
- **Pipeline Milestones**: UX111 BLA filed, DTX401 BLA expected mid-2025. Phase III data for UX143 (OI) and GTX-102 (Angelman) anticipated 2025.
- **Gene Therapy Leadership**: First commercial gene therapy (UX111) on track for mid-2025 approval. Manufacturing transition for DTX401 reduces costs.
- **Operational Efficiency**: 2024 cash used in operations down 10% vs. 2023. GAAP profitability target: 2027.
- **Clinical Highlights**: 67% fracture reduction in UX143 Phase II, complete enrollment for GTX-102 Phase III, and OTC protocol amendment for patient-centric design.


**【CEO Summary Section】**
- Total revenue for 2024 reached $560 million, a 29% increase from 2023, driven by strong performance across all commercial products. Crysvita contributed $410 million, with Latin America and Turkey seeing 78% growth.
- The company filed its first BLA for UX111 (Sanfilippo gene therapy) and expects a second BLA for DTX401 (GSDIa gene therapy) in mid-2025. If approved, the pipeline could expand to 6 commercial products.
- International growth highlights include Evkeeza launches in Europe, Canada, and Japan, and Dojolvi named patient sales in 14 EMEA countries.
- The company remains on track for GAAP profitability by 2027, with a focus on cost control and operational efficiency.

**【CFO Financial Commentary】**
- 2024 net loss was $569 million, reflecting significant R&D investments ($698 million) and SG&A expenses ($322 million). Cash reserves stood at $745 million as of December 2024.
- 2025 revenue guidance is $640-$670 million, driven by Crysvita growth in Latin America, Dojolvi penetration in XLH, and Evkeeza expansion in Europe and Japan.
- Key 2025 milestones include UX111 FDA approval (mid-2025), DTX401 BLA submission, and Phase III data reads for UX143 (osteogenesis imperfecta) and GTX-102 (Angelman syndrome).

**【CMO Clinical Updates】**
- UX143 (osteogenesis imperfecta): Phase III Orbit study interim analysis expected mid-2025. Phase II data showed 67% fracture rate reduction, with no new fractures in 14-month follow-up.
- GTX-102 (Angelman syndrome): Enrollment complete for Phase III Aspire study (122 patients). Aurora protocol under review to expand to younger patients and other genotypes.
- DTX401 (GSDIa): BLA submission expected mid-2025, with manufacturing transition to Bedford facility to improve quality and reduce costs.
- DTX301 (OTC deficiency): Protocol amendment allows ammonia reduction assessment through week 36, with diet/drug removal assessed up to 64 weeks.

**【Q&A Highlights】**
- **OI Interim Analysis**: 67% fracture rate reduction in Phase II suggests potential for second interim success in Orbit. Final analysis likely by end-2025 if interim fails.
- **Gene Therapy Launch Strategy**: Learning from Zolgensma, prioritizing payer engagement and rapid patient access for UX111. Commercial teams will leverage existing infrastructure from Dojolvi/Mepsevii launches.
- **OTC Protocol Changes**: Patient feedback led to blinded ammonia reduction assessment, followed by unblinded diet/drug removal. Design increases power while maintaining patient safety.
- **2025 Catalysts**: 3 potential approvals (UX111, DTX401, DTX301), Phase III data reads for UX143 and GTX-102, and Evkeeza/Japan launches.


Actual										-2.05	0.41	-1.13	-0.37	-2.03	-1.81	-1.08	-1.79	-2.19	-2.26	-3.5	-2.16	-2.33	-2.25	-2.23	-1.52	-2.03	-1.52	-1.4	-1.39	-1.57	-1.17	-1.81	-1.29
Forecast										-1.62	-1.5887	-1.2833	-1.1616	-1.2426	-1.3225	-1.3935	-1.3735	-1.781	-1.7505	-1.811	-2.135	-1.9923	-2.0904	-2.0773	-1.7074	-1.7472	-1.6607	-1.4839	-1.3085	-1.5978	-1.2972	-1.2339	-1.0926
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-26.54%	+125.81%	+11.95%	+68.15%	-63.37%	-36.86%	+22.50%	-30.32%	-22.96%	-29.11%	-93.26%	-1.17%	-16.95%	-7.63%	-7.35%	+10.98%	-16.19%	+8.47%	+5.65%	-6.23%	+1.74%	+9.81%	-46.69%	-18.07%

RARE

RARE fundamentals

RARE Q4 2025 Earnings

Earnings Call

You can ask Aime

RARE

RARE fundamentals

RARE Q4 2025 Earnings

Earnings Call

RARE Earnings Call Summary for Q4/20255:00 PM on Feb 12, 2026

RARE Earnings Call Summary for Q3/20255:00 PM on Nov 4, 2025

RARE Earnings Call Summary for Q2/20255:00 PM on Aug 5, 2025

RARE Earnings Call Summary for Q1/20255:00 PM on May 6, 2025

RARE Earnings Call Summary for Q4/20245:00 PM on Feb 13, 2025

You can ask Aime